Kuros BiosciencesCSBTF 72 Debt-to-Equity is 0.02 as of Dec. 2025, which is 33% below its 10-year median of 0.03. GuruFocus rates CSBTF with a GF Score™ of 72/100 and a GF Value™ of $54.78 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 92.35% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kuros Biosciences's Debt-to-Equity or its related term are showing as below:
CSBTF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 0.04
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Kuros Biosciences was 0.04. The lowest was 0.02. And the median was 0.03.
CSBTF's Debt-to-Equity is ranked better than 92.35% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs CSBTF: 0.02
Kuros Biosciences (OTCPK:CSBTF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kuros Biosciences Debt-to-Equity Related Terms
Kuros Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a Debt-to-Equity of 0.02 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kuros Biosciences and its competitors. This is 33% below median its historical median of 0.03. Over the past decade, Kuros Biosciences' Debt-to-Equity has ranged from 0.02 to 0.04. According to the industry distribution chart, Kuros Biosciences ranks #54 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 7.6%.
Is Kuros Biosciences' Debt-to-Equity too high?
Kuros Biosciences' current Debt-to-Equity of 0.02 is 33% below median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.04. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Kuros Biosciences' value of 0.02 is 91.1% below this industry median. Based on the distribution chart, Kuros Biosciences ranks #54 out of 706 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kuros Biosciences has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #54 out of 706 companies for Debt-to-Equity. This places Kuros Biosciences in the top 8% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Kuros Biosciences' value of 0.02 is 91.1% below this benchmark. Historically, Kuros Biosciences' own Debt-to-Equity has ranged from 0.02 to 0.04 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.23, Kuros Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Debt-to-Equity of 0.02 is 91.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Debt-to-Equity is 0.02, which is 33% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.78, compared to a current price of $25.57 — trading 53.3% below its estimated fair value. The current Debt-to-Equity is 0.02, which is 33% below median its 10-year median of 0.03 and 91.1% below the Medical Devices & Instruments industry median of 0.23. Kuros Biosciences' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Debt-to-Equity is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $25.57 is trading 53.3% below its estimated GF Value™ of $54.78.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Debt-to-Equity: 0.02 (33% below median its 10-year median of 0.03)
GF Value™: $54.78 vs. price of $25.57 (53.3% below fair value)
Industry Position: 91.1% below the Medical Devices & Instruments median (#54 of 706)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
72GF Score
Get the complete analysis for CSBTF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
